Gritsenko Taras Alekseevich,Гриценко Тарас Алексеевич,Davydkin Igor Leonidovich,Давыдкин Игорь Леонидович,Osadchuk Aleksej Mikhajlovich,Осадчук Алексей Михайлович,Shpigel Aleksandr Semenovich,Шпигель
申请号：
RU2017146134
公开号：
RU2667651C1
申请日:
2017.12.26
申请国别(地区):
RU
年份:
2018
代理人:
摘要：
FIELD: medicine.SUBSTANCE: invention relates to medicine and can be used to treat the erosive form of gastroesophageal reflux disease in patients put on chemotherapy. For this purpose, omeprazole is prescribed to patients at a dose of 20 mg twice a day for 7 days. In determining the refractivity of the erosive form of gastroesophageal reflux disease by the 7 day treatment of omeprazole, which consists in the absence of a decrease in the overall intensity of clinical symptoms by less than 50 % according to the visual analogue scale, prescribe omeprazole in a doubled dose. When verifying the refractivity of the erosive form of gastroesophageal reflux disease to 7 day treatment with a double dose of omeprazole, which consists in the absence of a decrease in the overall intensity of clinical symptoms by less than 50 % in accordance with the visual analogue scale and the absence of positive dynamics of the endoscopic picture of the mucosa of the esophagus according to the data of fibro-esophagogastroduodenoscopy, additionally prescribe ursodeoxycholic acid at a dose of 250 mg 3 times a day. Conduct a control of the erosion of the esophagus mucosa by means of fibro-esophagogastroduodenoscopy every 2 weeks. When ascertaining the healing of erosions in the mucous membrane of the esophagus, the dose of omeprazole is reduced to 20 mg twice a day, while taking ursodeoxycholic acid 250 mg 3 times daily for the whole period of chemotherapy, but not less than 16–24 weeks.EFFECT: invention makes it possible to reduce the risk of adverse outcomes (preservation of heartburn, pain, eructations) in the treatment of erosive forms of gastroesophageal reflux disease in patients put on chemotherapy.1 cl, 1 exИзобретение относится к медицине и может быть использовано для лечения эрозивной формы гастроэзофагеальной рефлюксной болезни у пациентов, получающих химиотерапию. Для этого пациентам назначают омепразол в дозе 20 мг 2 раза в сутки в течение 7 дней. При определении рефрактерности эроз
